TABLE 2.
Prognostic factors affecting OS in the entire ATLL patient cohort
| Variables | Number a | Univariate | Multivariate | ||
|---|---|---|---|---|---|
| HR (95% CI) | P‐value | HR (95% CI) | P‐value | ||
| ECOG PS | |||||
| 0, 1 | 87 | 1.000 | Reference | 1.000 | Reference |
| 2, 3, 4 | 26 | 3.272 (1.789‐5.985) | .0001 | 3.369 (1.492‐7.612) | .004 |
| Clinical variant | |||||
| Indolent | 10 | 1.000 | Reference | 1.000 | Reference |
| Aggressive | 103 | 2.997 (0.729‐12.319) | .128 | 2.207 (0.523‐9.314) | .281 |
| Age (years) | |||||
| ≤70 | 80 | 1.000 | Reference | 1.000 | Reference |
| >70 | 33 | 1.138 (0.627‐2.068) | .671 | 1.363 (0.717‐2.593) | .345 |
| Serum sIL‐2R (U/mL) | |||||
| ≤20 000 | 71 | 1.000 | Reference | 1.000 | Reference |
| >20 000 | 42 | 1.908 (1.099‐3.309) | .022 | 1.194 (0.632‐2.255) | .585 |
| Serum Alb (g/dL) | |||||
| ≥3.5 | 80 | 1.000 | Reference | 1.000 | Reference |
| <3.5 | 33 | 1.807 (1.033‐3.162) | .038 | 1.502 (0.669‐3.373) | .324 |
| CD28 protein overexpression | |||||
| Absence | 60 | 1.000 | Reference | 1.000 | Reference |
| Presence | 53 | 2.371 (1.368‐4.109) | .002 | 2.149 (1.207‐3.827) | .009 |
Abbreviations: Alb, albumin; ATLL, adult T‐cell leukemia/lymphoma; CI, confidence interval; ECOG, Eastern Cooperative Oncology Group; HR, hazard ratio; OS, overall survival; PS, performance status; sIL‐2R, soluble interleukin‐2 receptor.
a
Of the 120 patients, seven were excluded because of missing data.